IDT Australia tips sharp earnings improvement on Sanofi tie-up and US policy tailwinds

IDT Australia Limited ( (AU:IDT) ) has issued an announcement.

IDT Australia has reported that, despite a weak March quarter due to a scheduled maintenance shutdown and seasonal public holidays, it expects its best fourth-quarter performance since launching a transformation program more than two years ago. The company forecasts full-year FY26 operating revenue from its three core verticals to rise to $15 million-$16 million and its EBITDA loss to narrow sharply to $1.5 million-$2 million from $6.3 million in FY25.

Management’s strategic reset is focused on cost optimisation, higher-value repeat business and a $2 million cost-saving initiative slated to benefit FY27, positioning the business to withstand economic and fuel-cost pressures. Growth prospects are underpinned by IDT’s new status as a Preferred Vendor to Sanofi, recommissioning of mothballed facilities, and rising demand in psychedelics and cannabinoid medicines following favourable US policy shifts.

The Preferred Vendor designation from Sanofi, secured after supporting development of mRNA vaccines, gives IDT access to bid on additional programs across multiple therapeutic areas and dosage forms. Participation in upcoming US industry events through a partnership with Fierce Pharma and support from Sanofi is expected to broaden its exposure to key pharmaceutical decision makers and could further strengthen its global client pipeline.

IDT is already winning new work from an emerging controlled-drug manufacturer targeting the US market, demonstrating early benefits from regulatory changes that encourage psychedelic-assisted therapies and cannabinoid-based treatments. Together with improved operational leverage from recommissioned facilities, these developments signal a potential turning point toward more sustainable revenue growth and a significantly reduced earnings shortfall for stakeholders.

More about IDT Australia Limited

IDT Australia Limited is a pharmaceutical manufacturing company based in Boronia, Victoria, specialising in high-potency and high-containment drugs for local and international clients. Operating cGMP-compliant facilities audited by the US FDA and Australian TGA, it offers end-to-end services from new drug development and scale-up to commercial API production and oral and injectable finished dose forms.

Average Trading Volume: 222,217

Technical Sentiment Signal: Sell

Current Market Cap: A$16.45M

Find detailed analytics on IDT stock on TipRanks’ Stock Analysis page.